FMP
Seelos Therapeutics, Inc.
SEEL
NASDAQ
Inactive Equity
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
0.37 USD
0 (0%)
2023
2022
2021
2020
2.2M
0
0
0
30.12M
53k
0
0
-27.91M
-53k
0
0
12.59M
70.92M
61.67M
18.76M
30.12M
58.62M
46.65M
10.98M
12.53M
12.3M
15.02M
7.78M
-57k
0
0
0
12.59M
12.3M
15.02M
7.78M
0
-3.02M
230k
0
-40.5M
-70.92M
-61.67M
-18.76M
2.62M
-2.62M
-4.38M
-342k
-37.88M
-73.53M
-66.05M
-19.1M
0
2.6M
1.49M
119k
-37.88M
-76.14M
-67.53M
-19.22M
-7.73
-21.48
-22.29
-12.88
-7.73
-21.48
-22.29
-12.88
4.9M
3.54M
3.03M
1.49M
4.9M
3.54M
3.03M
1.49M
-37.75M
-73.47M
0
0
2023
2022
2021
2020
-214.74M
-141.21M
-75.16M
-56.06M
-37.88M
-76.14M
-67.53M
-19.22M
-1.2M
0
0
0
0
0
0
0
-252.63M
-214.74M
-141.21M
-75.16M
-39.08M
-73.53M
-66.05M
-19.1M
2023
2022
2021
2020
15k
72k
39k
0
57k
53k
61.67M
18.76M
0
0
0
0
-42k
19k
-61.63M
-18.76M
2023
2022
2021
2020
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.